Ecor1 Capital Llc bought 15,000 shares as the company's stock rose 1.68% with the market. The institutional investor held 144,800 shares of the health care company at the end of 2017Q3, valued at $7.88 million, up from 95,500 at the end of the previous reported quarter. The total amount of shares outstanding is 145.29 million, giving the company a market capitalization of about 7.76 billion. The stock increased 0.60% or $0.31 during the last trading session, reaching $52.09. About 502,450 shares traded.
In the past 52-week period, shares of Seattle Genetics, Inc. It has outperformed by 85.30% the S&P500. About 1.17M shares traded. The institutional investor held 11.04M shares of the restaurants company at the end of 2017Q3, valued at $448.43M, down from 11.42M at the end of the previous reported quarter. The stock decreased 3.00% or $1.6 during the last trading session, reaching $51.78. Whittier Tru Com Of Nevada Inc accumulated 189 shares or 0% of the stock. It has underperformed by 3.04% the S&P500. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Therefore 28% are positive. Regulus Therapeutics had 27 analyst reports since August 5, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 14 by RBC Capital Markets. Stifel Nicolaus maintained it with "Hold" rating and $5600 target in Friday, July 7 report. BMO Capital Markets has "Buy" rating and $2300 target. (NASDAQ:SGEN) rating on Friday, October 27. The stock of A. O. Smith Corporation (NYSE:AOS) earned "Buy" rating by BB&T Capital on Wednesday, September 23. (NASDAQ:SGEN) earned "Neutral" rating by Credit Suisse on Monday, December 12. The stock of K12 Inc. The firm has "Overweight" rating by Barclays Capital given on Monday, October 26.
Investors sentiment decreased to 1.22 in 2017 Q3.
Since January 1, 0001, it had 0 insider purchases, and 17 sales for $9.99 million activity. 73 funds opened positions while 118 raised stakes.
Bnp Paribas Arbitrage Sa, which manages about $40924.49B US Long portfolio, upped its stake in Liberty Media Corp Delaware by 103 shares to 2,774 shares, valued at $105.66M in 2017Q3, according to the filing. (NASDAQ:USLM). Renaissance Limited Co holds 188,201 shares or 0.02% of its portfolio. Commonwealth Fincl Bank Of Aus invested in 0.01% or 24,900 shares. (NASDAQ:USLM) for 1,525 shares. Rmb Cap Mngmt Limited Liability Company reported 53,145 shares stake. Ecor1 Capital Ltd Llc invested 0.87% in Regulus Therapeutics Inc. Pacad Investment Limited reported 2,000 shares. Millennium invested 0% of its portfolio in Regulus Therapeutics Inc. Gsa Capital Prtnrs Llp holds 0.05% of its portfolio in Aramark (NYSE:ARMK) for 16,329 shares. State Street has invested 0% in K12 Inc. Thrivent For Lutherans owns 5,810 shares. Amp Investors Limited stated it has 0.01% in A. O. Smith Corporation (NYSE:AOS). Shine Invest Advisory Services invested in 157 shares or 0% of the stock. (NASDAQ:USLM) for 5,034 shares. Cleararc Capital stated it has 3,742 shares or 0.03% of all its holdings.
Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.52, from 1.3 in 2017Q2. (NASDAQ:SGEN) was sold by DOBMEIER ERIC on Thursday, August 31. 25 funds opened positions while 51 raised stakes. Its up 7.56% from 41.70 million shares previously. The company has an average rating of "Buy" and a consensus price target of $63.76. (NASDAQ:SGEN). Capital Investors invested in 4.46 million shares or 0.29% of the stock. Bristlecone Advisors LLC purchased a new position in shares of Seattle Genetics in the 3rd quarter worth about $180,000. Hsbc Holdg Pcl reported 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 189 shares. BlackRock Inc. lifted its stake in Seattle Genetics by 2.6% in the second quarter. (NASDAQ:SGEN). 2,762 are owned by Nordea Inv Management Ab. Jacobs Levy Equity Management Inc has 93,411 shares.
The analysts wrote, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M". (NASDAQ:SGEN). The New York-based Bancshares Of New York Mellon has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Macquarie Group Incorporated Ltd reported 0.01% of its portfolio in Seattle Genetics, Inc. First Mercantile Trust Communication holds 0.09% in Aramark (NYSE:ARMK) or 11,637 shares. (NASDAQ:CUTR). Hancock Hldg Communications has 0.01% invested in Cutera, Inc. (NASDAQ:SGEN) for 23,229 shares.
Analysts await Aramark (NYSE:ARMK) to report earnings on February, 6.
Among 16 analysts covering Bloomin' Brands (NASDAQ:BLMN), 3 have Buy rating, 1 Sell and 12 Hold. Therefore 39% are positive. RBC Capital Markets maintained the stock with "Outperform" rating in Friday, July 31 report. HIMES VAUGHN B also sold $305,423 worth of Seattle Genetics, Inc. The firm has "Hold" rating by Oppenheimer given on Tuesday, October 10. The firm has "Hold" rating given on Tuesday, August 29 by Cantor Fitzgerald. Needham maintained Seattle Genetics, Inc. The firm earned "Hold" rating on Wednesday, November 8 by Oppenheimer. On Tuesday, January 17 the stock rating was downgraded by Morgan Stanley to "Underweight". The firm has "Outperform" rating given on Friday, September 11 by William Blair. Goldman Sachs Grp reported 1.62 million shares. It also reduced its holding in Eog Resources Inc (NYSE:EOG) by 15,150 shares in the quarter, leaving it with 27,150 shares, and cut its stake in America Movil Sab De Cv L Adr (NYSE:AMX).
Since August 7, 2017, it had 0 buys, and 17 selling transactions for $9.99 million activity. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by SIMPSON TODD E on Wednesday, September 6. 18,832 Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by SIEGALL CLAY B. $1.31M worth of Seattle Genetics, Inc. OShea Timothy J sold $156,840 worth of stock. The insider Laber Larry sold 500 shares worth $20,250.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.